Leon Davis, MD
Internal Medicine · Montgomery, ALNPI 1265493134
Payments from drug & device makers
Across 855 payments — averaging $14.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$770
- Dexcom, Inc.$736
- Merck$572
- plus $6K from 52 others
Across 4 payments — averaging $3495.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi-aventis U.S. LLC$14K
What the payments were for
- Food & beverage$12,45899%
- Education$1051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$12,563 in reported general payments places this provider in the 90th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 271 | $383,928 |
| JardianceEmpagliflozin | 268 | $359,989 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 469 | $344,004 |
| OzempicSemaglutide | 203 | $274,081 |
| FarxigaDapagliflozin Propanediol | 232 | $253,968 |
| MounjaroTirzepatide | 187 | $240,812 |
| LinzessLinaclotide | 205 | $214,258 |
| RybelsusSemaglutide | 150 | $208,774 |
| EliquisApixaban | 206 | $200,481 |
| VraylarCariprazine Hcl | 90 | $143,672 |
| TrulicityDulaglutide | 105 | $130,810 |
| GemtesaVibegron | 92 | $104,751 |
| KerendiaFinerenone | 105 | $93,628 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 141 | $79,097 |
| MyrbetriqMirabegron | 81 | $76,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet, Verquvo, Belsomra | $572 | $484,875395 claims |
| Novo NordiskOzempic, Rybelsus | $770 | $482,856353 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,735 | $449,784665 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $277 | $423,721329 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $1,312 | $372,016306 claims |
| Lilly USA, LLCMounjaro, Trulicity | $306 | $371,622292 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $1,043 | $332,283376 claims |
| PfizerEliquis | $354 | $200,481206 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $57 | $104,75192 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $273 | $94,558105 claims |
| BayerKerendia | $406 | $93,628105 claims |
| Johnson & JohnsonXarelto | $354 | $57,54955 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Montgomery
- John PorterMontgomery$316K
- Joel McCloudMontgomery$27K
- John JerniganMontgomery$25K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.